Book a demo

Company intelligence

WuXi AppTec, Laboratory Testing Division

Dedicated to Your Success.

Pharmaceutical Manufacturing
Plainsboro, US
87 employees
Founded 1987
4 public signals

About WuXi AppTec, Laboratory Testing Division

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Our state-of-the-art Laboratory Testing Division provides leading bioanalytical & drug metabolism contract research services to a global customer base of pharmaceutical, biotech & agrochemical firms. Our bioanalytical services support a wide range of compounds-small & large molecules, new modalities including oligonucleotides, ADC, bispecific antibodies & more-from discovery to preclinical IND-enabling & regulated clinical studies. Capabilities include LC-MS/MS & immunochemistry platforms for GLP & non-GLP & customized Central Laboratory services to facilitate global clinical studies. Our comprehensive drug metabolism services are tailored to support the entire drug development cycle, from early discovery through IND-enabling to late-stage clinical development. Capabilities include in vivo pharmacokinetics, in vitro ADME, in vitro & in vivo biotransformation, & non-clinical radiolabel ADME (mass balance & QWBA).

Verified activity

Signals from WuXi AppTec, Laboratory Testing Division

4 published signals

Find the companies already in motion.

Customize signals around your market, buyers, competitors, and investment thesis.

© 2026 SeedOpsCompany intelligence.

SeedOps.